Inovio advances on rumours of leading pharma groups showing interest

Posted on by

Inovio {NASDAQ: IVO} – The UK based Daily Mail has reported large pharma companies “sniffing around”  and showing interest in their immunotherapy projects.

With immunotherapy having the potential to replace chemotherapy as the cancer solution in the next few years, it is perhaps not surprising that Inovio is appearing in their cross hairs.

Comment

Interesting that this was reported in a London newspaper, as Inovio are not that well known this side of the pond!

With increased media focus on the advantages of immunotherapy in the UK press earlier this week, predicting “the end of cancer”, it would appear that the journalist has done his homework and identified one of the principal companies that is advancing their projects in this field.

The Daily Mail article is  below

 

Healthy interest in Inovio Pharmaceuticals’s future as big pharma groups sniff around.

By GEOFF FOSTER FOR THE DAILY MAIL – PUBLISHED: 22:16, 4 June 2015 | UPDATED: 22:16, 4 June 2015

Medical experts this week told us that immunotherapy, which trains the immune system to attack cancerous cells, could replace chemotherapy as the standard treatment for cancer within the next five years.
The disease continues to kill people the world over and drug companies, big and small, continue to invest millions in research and development in the hope a magic cure could one day be found.
Should that ever happen, the lucky company would be worth an absolute fortune.
Inovio Pharmaceuticals advanced 3 per cent to $8.88 on industry gossip that leading pharma groups were sniffing around.

In the meantime, anyone with a potential blockbuster cancer treatment looks vulnerable and possible fodder for one of the major drug groups.

 

Inovio Pharmaceuticals advanced 3 per cent to $8.88 on industry gossip that leading pharma groups were sniffing around. Indeed, speculation is rife that GlaxoSmithKline, 26p cheaper at 1411.5p, has had an $18 (£11.70) a share cash offer already rejected by the Inovio board. With rivals Roche, Bristol Myers and Merck all believed to be interested, analysts reckon the eventual take-out price could be nearer $30 (£19.50) a share.